Recursion Pharmaceuticals Inc. (RXRX): Price and Financial Metrics

Recursion Pharmaceuticals Inc. (RXRX): $9.43

0.06 (+0.64%)

POWR Rating

Component Grades








RXRX Price/Volume Stats

Current price $9.43 52-week high $16.75
Prev. close $9.37 52-week low $4.97
Day low $9.24 Volume 916,167
Day high $9.55 Avg. volume 5,912,910
50-day MA $8.70 Dividend yield N/A
200-day MA $8.91 Market Cap 2.24B

RXRX Stock Price Chart Interactive Chart >

Recursion Pharmaceuticals Inc. (RXRX) Company Bio

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people’s lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

RXRX Latest News Stream

Event/Time News Detail
Loading, please wait...

RXRX Latest Social Stream

Loading social stream, please wait...

View Full RXRX Social Stream

Latest RXRX News From Around the Web

Below are the latest news stories about RECURSION PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RXRX as an investment opportunity.

40 Cities with the Highest Life Expectancy in the US

In this article, we look at 40 Cities With The Highest Life Expectancy In The US. You can skip our detailed analysis on companies that are working on longevity enhancement and improved health facilities by heading over directly to the 10 Cities With The Highest Life Expectancy In The US. Life expectancy of a newborn […]

Yahoo | December 22, 2023

Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry

Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets.KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries w

Yahoo | December 20, 2023

3 Genomics Stocks to Unlock the Future of Medicine

Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use.

Jeremy Flint on InvestorPlace | December 19, 2023

2 Cathie Wood Stocks That Might Be Smart Buys Right Now

These two biotech stocks hold enormous potential.

Yahoo | December 17, 2023

AI Meets Biotech: 3 Top Stocks Transforming Medical Science

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

John Blankenhorn on InvestorPlace | December 16, 2023

Read More 'RXRX' Stories Here

RXRX Price Returns

1-mo 0.11%
3-mo -14.81%
6-mo -4.17%
1-year N/A
3-year -74.11%
5-year N/A
YTD -4.36%
2023 27.89%
2022 -54.99%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!